LEXX News and Press, Lexaria Bioscience Corp. From 05/23/23

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering Earlier t...

(TheNewswire) DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility Kelowna, BC - TheNewswire - May 23, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”) , a ...

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than lea...

Lexaria’s patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is curre...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in ...

900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH KELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its animal study HOR-A22-1 has...

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, p...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, has announced the closing of its public offering of 2,106,000 units, with each consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold at a public of...

(TheNewswire) Kelowna, British Columbia – TheNewswire - May 11, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its public offering of 2,106,000 units,...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced completion of batch manufacturing of the DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for its upcoming U.S. phase 1b hypertension clinical trial HYPER-H23...